Expanded Access to REGN4461 for Patients With Diseases Associated With Deficient Leptin Signaling

NCT04710056 · clinicaltrials.gov ↗

AVAILABLE

Status

INDUSTRY

Sponsor class

Conditions

Lipodystrophy
Generalized Lipodystrophy (GLD)
Monogenic Obesity (MOB)

Interventions

DRUG: REGN4461

Sponsor

Regeneron Pharmaceuticals